Illumina completed the acquisition of Fluent BioSciences.

Illumina, a DNA sequencing and array-based technologies company, completed the acquisition of Fluent BioSciences, a developer of an emerging and highly differentiated single-cell technology. Financial terms were not disclosed. "The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy. Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers," Steven Barnard, Illumina Chief Technology Officer.